Oxford Expression Technologies, the award-winning specialist
provider of baculovirus-based protein expression solutions, has launched
baculoFECTIN. This new non-toxic transfection reagent has been optimized for
use in insect cells and proven to produce greater levels of transfection -
leading to high level protein expression.
The transfection spectrum comprises various established cell lines and primary
cells. baculoFECTIN consists of two components, a positively charged polymer
with DNA-binding capacity that is embedded into a novel porous nanoparticle.
The complete nanoparticle complex protects the bound DNA from degradation by
nucleases. Only the DNA nanoparticle complex with its unique size can be
preferentially taken up by the cells. Within the cells, the released
DNA-nanoparticle complexes are protected against DNA degradation.
"The main benefits of baculoFECTIN compared with lipid-based products are
that it has a quick, effective and easy protocol, from co-transfection to high
titre seed stock; it is non-toxic so cell health and viability is maintained;
and the nanoparticle/polymer duplex optimizes entry into cells and stabilizes
the DNA within transfected insect cells," said Richard Broadhead, sales
and marketing manager at Oxford Expression Tehnologies. "Stable for up to
a year, baculoFECTIN is the perfect companion to our leading baculovirus
expression system flashBAC. It is ideal for high-throughput transfection
experiments."
About Oxford Expression Technologies:
Oxford Expression Technologies is a biotechnology company and centre of
excellence for baculovirus protein expression. Specializing in the use of the
baculovirus expression vector system, a eukaryotic expression system that can
express a large variety of recombinant proteins, Oxford Expression Technologies
provides protein expression products, services and consultancy to many global
pharmaceutical companies. The Company’s proprietary flashBAC technology enables
large amounts of a given protein to be produced in culture. Its internationally
renowned expertise and products enable proteins to be produced faster, more
easily and cost-effectively using automated and high-throughput methods
compared with other baculovirus expression systems. This contributes to the
development of new drugs and research targeted towards understanding how
proteins work in health and disease.
The company was founded in 2007 as a result of collaboration between Oxford
Brookes University and the Natural Environment Research Council to provide
researchers with custom proteins for research purposes.
Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St
Stamford, Lincolnshire PE9 2UY
+44 (0)773 403 2112
